The possible association of ACE polymorphism with ischemic stroke (IS) was evaluated in 65 patients with IS and 330 age and BMI-matched controls. ACE genotypes were determined by polymerase chain reaction (PCR). There was no significant difference in ACE genotype/allele frequencies between case and control group (p>0.05). Patients with D allele had 4,7 times higher risk for large vessel IS than healthy persons D allele possessors. Persons with D allele had 9.2 times higher risk for large vessel disease than small vessel disease. These data suggest a possible association of ACE gene polymorphism with pathogenesis of large vessel IS.
INTRODUCTION
Stroke is a complex, multifactorial disease. It is one of the leading causes of disability and death. About 80% of all strokes are ischemic and have a polygenic basis. Advances in genetic epidemiology have revealed that some genetic variants increase the risk for IS. Evidence suggests that genetic variation in the rennin angiotensin-aldosterone system (RAAS) contributes to the risk of ischemic stroke. Among the various sequence variations in RAAS, the insertion/deletion (I/D) polymorphism in angiotensin I-converting enzyme (ACE) is the most extensively studied.
ACE is a dipeptidyl carboxylase that converts angiotensin I into the antinatriuretic vasoactive angiotensin II, an octapeptide involved in vasoconstriction, aldosterone production, and norepinephrine release from sympathetic nerve endings and inactivates bradykinin, a vasodilator and natriuretic substance. ACE is encoded by a 21-kb 26 exons gene located on chromosome 17 at q23. A deletion polymorphism in the ACE gene consists of the absence of a 287-bp Alu repetitive sequence in reverse orientation near the 3' end of intron 16 . Mean ACE activity concentration in DD carriers are around twice those found in II carriers (1, 2) . 
DISCUSSION
This is the first study in Serbia that has examined the effect of ACE I/D gene polymorphism on IS risk. No significant evidence was provided to support our hypothesis that ACE gene polymorphism may represent a susceptibility mutation for IS. Previous reports on ACE gene polymorphism and IS produced conflicting results as to the importance of ACE alleles in predisposition to IS. We compiled results from 7 meta-analyses and 53 case-control studies (Table 4) . (11) . However, this result was not replicated in another study using a larger population of lacunar infarction patients (n=130) (9). Watanabe et al. (18) showed no association of the ACE polymorphism with SBI in a smaller population (n=36). Takami et al. (64) failed to show an association with number of lacunae in 134 Japanese patients.
Discrepancy in the obtained results can be explained by heterogeneity of study designs employed, differences in inclusion and exclusion criteria, ethnically different patient populations, small sample sizes, unmatched controls, combinations of ischemic and hemorrhagic strokes, different stroke subtypes and age of stroke onset, type of statistical evaluation, covariates, correction for multiple testing, and other factors that affect many publications.
There is less literature data about the association of serum lipids and apolipoproteins with ACE I/D polymorphism in patients with IS. The results of our study are consistent with two previously published studies. Del Ser et al. (65) showed that serym triglycerides concentration is elevated in stroke patients with DD ACE genotype. Sertić et al. (14) found significant association of triglycerides concentration and DD genotype (DD>ID=II). It can be hypothesized that the increased serum triglycerides level in DD ACE genotype could be a feature of an insulin resistence syndrome and determine atherogenic and thrombogenic risk (65) .
Agerholm-Larsen et al. (66) determined the effect of ACE genotype on serum ACE activity in 900 women and men from the Copenhagen City Heart Study and found that ACE gene polymorphism explains 30-40% of variability in serum ACE activity and this effect was codominant, with DD subjects having the highest, ID subjects intermediate, and II subjects the lowest serum ACE activity. The relatively small number of published studies with contradictory results examined the association between ACE activity and ACE I/D polymorphism in patients with IS compared to the number of studies that examined only the association of ACE I/D polymorphism polymorphism with IS.
Our study showed expected trend in ACE activity (DDIDII) in patient and control groups. Patients with DD genotype had significantly higher ACE activity (p0,05) compared with controls. This result is in accordance with croatian study (patients with angiographicaly proved cerebral atherosclerosis) (14) . Dikmen et al. (46) examined Turkish acute stroke patients (185) although ACE activity was high in DD genotype, no difference was determined to ACE enzyme activity according to ACE genotypes in patients and controls. Some studies suggested that D allele of the ACE gene is a marker of an elevated circulation ACE level. Catto et al. (9) reported plasma ACE activity significantly lower in stroke patients (cerebral infarction or cerebral hemorrhage) than in controls, and levels of ACE activity were significantly lower during the acute phase of stroke but were similar to level of control activity after 3 months. Markus et al. (7) found that patients with IS and DD genotype has higher ACE activity compared with carriers of II genotype.
We expect that subsequent genome-wide association studies in large and well-characterized groups of patients of different ethnic origin will contribute substantially in the near future to a better understanding of the pathophysiology underlying ischemic stroke and permit the identification of new therapeutic targets aimed at stroke prevention and neuroprotection from ischemic injury.
